EBCI helps PCNSL patients understand the results from ONO PHARMA's recent phase II PROSPECT study, which tested the safety and efficacy of tirabrutinib. REDMOND, WA, UNITED STATES, December 23, 2025 / EINPresswire.com / -- ONO PHARMA recently announced positive results from the phase II PROSPECT study, which tested the safety and efficacy of tirabrutinib is in U.S. patients with relapsed (came back after treatment) or refractory (didn’t respond to treatment) Primary Central Nervous System Lympho

CMTA announces a $100,000 investment in EverTree Bio following early CMT1A testing through the CMTA Preclinical Toolbox, supporting continued research progress. EverTree’s approach aligns with our mission to advance strong, patient-focused science that may be ignored. Our goal is to ensure programs like this are not stalled by early-stage funding gaps.” — Sue Bruhn, PhD, CMTA CEO GLENOLDEN, PA, UNITED STATES, December 23, 2025 / EINPresswire.com / -- The Charcot-Marie-Tooth Association (CMTA) an

Scientists present a new approach that could empower the immune system to combat cancer cells and pave the way for new treatments for this deadly disease. SHARJAH, EMIRATE OF SHARJAH, UNITED ARAB EMIRATES, December 23, 2025 / EINPresswire.com / -- Researchers at the University of Sharjah are exploring a promising approach that could enhance the immune system’s ability to fight cancer, potentially paving the way for new treatments. In a recent article published in the journal Cell Death & Disease

Training equips midwives in rural Sololá to identify cardiac warning signs in newborns and improve early referral for life-saving care. By equipping midwives with practical screening knowledge, we are strengthening frontline care and expanding access to early diagnosis and life-saving treatment.” — Christina Lindseth, International Director of Cardiac Care SOLOLA, GUATEMALA, December 23, 2025 / EINPresswire.com / -- Love Without Boundaries (LWB), an international charity serving children worldwi

A non-invasive, high-accuracy surveillance test for bladder cancer has the potential to improve patient experience, streamline workflows, and reduce overall cost of care” — Megann Vaughn Watters, Vice President of New Ventures for Labcorp BOSTON, MA, UNITED STATES, December 23, 2025 / EINPresswire.com / -- Cellens, Inc., a cancer diagnostics company pioneering a new mechanobiology and AI-driven platform, BioFeel™, for non-invasive cancer detection, has raised a $6.5M Series Seed round. The finan

Delivery Method: Via Email Product: Drugs Recipient: Pinnacle Professional Research dba Pinnacle Peptides 1001 N Elm Street, Suite 31 Greensboro , NC 27401 United States service@pinnaclepeptides.com Issuing Office: Center for Drug Evaluation and Research (CDER) United States WARNING LETTER December 12, 2025 RE: 719337 Pinnacle Professional Research dba Pinnacle Peptides: This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address ht

Delivery Method: Via Electronic Mail - Delivery and Read Receipt Requested Product: Drugs Recipient: Recipient Name Aaron M. Schneider Recipient Title Chief Pharmacy Officer & Owner Revive Rx LLC dba Revive Rx Pharmacy 3831 Golf Drive, Suite A Houston , TX 77018-5218 United States Issuing Office: Center for Drug Evaluation and Research (CDER) United States WARNING LETTER WL # 709509 September 22, 2025 Dear Mr. Schneider: From January 27, 2025, to February 7, 2025, a U.S. Food and Drug Administra

Delivery Method: Via Email Reference #: 320-26-29 Product: Drugs Over-the-Counter Drugs Recipient: Recipient Name Mr. Zhou Yigang Recipient Title Production Manager Guangdong Renhe Guozhuang Biotechnology Co., Ltd. No. 5, Tongfu Road, Xicheng Industrial Area Renhe Town Baiyun Qu Guangzhou Shi Guangdong Sheng , 510080 China Issuing Office: Center for Drug Evaluation and Research (CDER) United States Warning Letter 320-26-29 December 16, 2025 Your facility is registered with the United States Food

The FDA has become aware of a potentially high-risk device issue. The FDA will keep the public informed and update this web page as significant new information becomes available. Affected Product The FDA is aware that Integra LifeSciences has issued a letter to affected customers recommending certain Codman Microsensor Basic Kits and Cerelink ICP Sensor Basic Kits be removed from where they are used or sold. Affected devices: Full list of affected lots What to Do Identify affected lots and remov

CAMBRIDGE, Mass., Dec. 23, 2025 /PRNewswire/ -- Next Gen Diagnostics (NGD) today announced that January 1 the Company will spin off its Infection Prevention division into an independent company, NGD Infection Prevention, focused on the implementation of real-time genomic transmission detection across U.S. hospitals. The move is in response to the broadening recognition that sequencing of infection has become a practical means to detect and prevent transmission in hospitals and control the asso